EXECUTIVE SUMMARY FOR EXPERT REVIEWERS [4]

EXECUTIVE SUMMARY FOR EXPERT REVIEWERS
DOCUMENT A.5 — STANDARDIZED GLOSSARY [4]

1. Document Purpose [4]

A.5 is a bilingual (Vietnamese–English) quick reference table for the entire document series. While A.4 provides detailed operational definitions and international comparisons for each term, A.5 aggregates all terms, biomarkers, imaging modalities, and abbreviations into 6 subject groups in table format — serving as a quick reference when reading any document from A.0 to C.4 [4].

2. Structure of 6 Subject Groups [5]

Group	Content
Group 1 [5]	Four verification targets: Crystal-free (joints/tendons/soft tissues), Delaying dialysis (CKD), Reducing cardiovascular decompensation, Cirrhosis recompensation. Each target includes: target organ, verification modality, quantitative objective, action threshold [5].
Group 2 [5]	60 HOW terms: All terms from A.4: Group A (7 international), Group B (18 equivalent), Group C (35 developed by Vien gut). Each term includes: code, VN name, EN name, source group [5].
Group 3 [5]	28 biomarkers and thresholds: Biochemical, hematological, immunological, and urine tests. Each marker includes: name, unit, reference range, HOW action threshold, corresponding SLA. For example: K⁺ >6 mmol/L → SLA 4h; Cortisol <3 µg/dL → SLA 4h [5].
Group 4 [6]	18 imaging modalities: OMERACT joint ultrasound, kidney ultrasound, echocardiography (Simpson’s EF), FibroScan, DECT, X-ray, tissue elastography. Each modality includes: name, supported verification target, monitoring parameters, frequency [6].
Group 5 [6]	Cited international guidelines: All guidelines cited in the series: ACR 2020, EULAR 2016, KDIGO 2024, ESC 2021, EASL 2018, NICE NG56, WHO ICOPE, ADA 2024, etc [6].
Group 6 [6]	77+ abbreviations: Standardized abbreviations: sUA, eGFR, ULT, T2T, MDT, SLA, BNP, EF, CKD, DECT, DCS, MSU, RRT, MELD, etc [6].

3. Highlights — Group 1: Four Verification Targets [7]

Target	Target Organ	Verification Modality	Action Threshold
1. Crystal-free [7]	Joints, tendons, soft tissues [7]	OMERACT Ultrasound + DECT + X-ray [7]	sUA >6 mg/dL x 2 → increase ULT; <5 when tophi present [7]
2. Delaying dialysis [7]	Kidney parenchyma, GFR [7]	eGFR CKD-EPI 2021 + Kidney Ultrasound + Elastography [7]	eGFR decrease >25%/3 months → withdraw SLA; <15 → RRT consultation [7]
3. Reducing heart decompensation [7]	Myocardium, heart valves [7]	Simpson’s EF Echo + NT-proBNP + Troponin [7]	NT-proBNP increase >50% → SLA 24h; EF decrease >10% → escalate tier [8]
4. Cirrhosis recompensation [8]	Liver parenchyma, fibrosis [8]	FibroScan + Liver Ultrasound + Albumin + PT-INR + Child–Pugh [8]	Albumin <2.8 → SLA 48h; new ascites → urgent consultation [8]

4. Relationship between A.4 and A.5 [8]

A.4 = operational dictionary (full definitions + international comparison). A.5 = quick reference table (name + threshold + SLA + abbreviation). The two documents complement each other: A.5 for quick lookups → A.4 for deep reference when context is needed [8].

5. Position in the Document System [8]

A.5 is the final document of Part A — Foundation. After A.5, the reader has sufficient theoretical framework (A.1), definitions (A.2), gap evidence (A.3), operational dictionary (A.4), and quick reference tables (A.5) to proceed to Part B (operations) and Part C (verification targets). Document A.5 is continuously updated as new terms emerge [8].

REFERENCES (Abridged) [9]

• [1] FitzGerald JD, et al. 2020 ACR Guideline for Gout. Arthritis Care Res. 2020;72(6):744–760 [9].
• [2] Richette P, et al. 2016 EULAR recommendations for gout. Ann Rheum Dis. 2017;76(1):29–42 [9].
• [3] KDIGO. 2024 Clinical Practice Guideline for CKD. Kidney Int. 2024; Supplement [9].
• [4] McDonagh TA, et al. 2021 ESC Guidelines for heart failure. Eur Heart J. 2021;42(36):3599–3726 [9].
• [5] EASL. Clinical Practice Guidelines for decompensated cirrhosis. J Hepatol. 2018;69(2):406–460 [9].

Note: For the full reference tables (60 terms, 28 biomarkers, 18 imaging modalities, 77+ abbreviations, 37 references), see the full-text version of A.5 [10].

Vien gut is ready to share the entire model with the international medical community as a public asset, serving the goal of improving care for complex chronic multimorbidities in 129 low- and middle-income countries [10].

Full document system: A.0–A.5 | B.1–B.5 | C.1–C.4 | Part D [10]